Rinesh Ram Mohan1,2, Nour El Huda Abd Rahim2*, Norlelawati A. Talib3, Norbaiyah Mohamed Bakrim2, Mohd Asyraf Abdull Jalil2, Siti Norain Mat Rasid2
1. Department of Pharmacology, Faculty of Medicine, Universiti Sultan Zainal Abidin, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Terengganu Darul Iman, Malaysia
2. Department of Basic Medical Sciences, Kulliyyah of Medicine, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, Bandar Indera Mahkota, 25200 Kuantan, Pahang Darul Makmur, Malaysia
3. Department of Pathology and Laboratory Medicine, Kulliyyah of Medicine, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, Bandar Indera Mahkota, 25200 Kuantan, Pahang Darul Makmur, Malaysia
*Corresponding author: Nour El Huda Abd Rahim.
ABSTRACT
INTRODUCTION: Obesity commonly co-occurs in patients with schizophrenia, contributing to their elevated susceptibility to cardiovascular disease. Apolipoprotein A1 (Apo A1), the principal protein component of high-density lipoprotein (HDL), is known for its protective roles against inflammation and atherosclerosis; however, the relationship of obesity among individuals with schizophrenia remains unclear.
OBJECTIVE(S): This study aimed to compare the plasma Apo A1 levels between individuals with schizophrenia and control subjects across both obese and non-obese groups.
MATERIALS & METHODS: A total of 120 subjects participated in this comparative cross-sectional study. They were categorised into four subgroups: obese schizophrenia, obese control, non-obese schizophrenia, and non-obese control (n = 30 per group). Plasma Apo A1 concentrations were quantified using a sandwich Enzyme-Linked Immunosorbent Assay (ELISA). The Mann-Whitney U test was applied to non-normally distributed obese groups, and Welch’s t-test to non-obese groups with unequal variances.
RESULTS: Plasma Apo A1 levels were significantly reduced in individuals with schizophrenia across both obesity categories. In the obese participants, the schizophrenia group demonstrated significantly lower median Apo A1 (270.20 [153.36] mg/dL) compared to obese controls (308.65 [132.85] mg/dL) (p = 0.016). A similar trend was observed in the non-obese group, mean Apo A1 was also lower in non-obese schizophrenia participants (333.55 ± 131.03 mg/dL) than in non-obese controls (459.23 ± 206.92 mg/dL) (p = 0.004). These findings establish that schizophrenia independently lowers Apo A1 levels, while co-morbid obesity significantly exacerbates this deficit, increasing cardiovascular risk in these patients.
CONCLUSION: Our findings show that individuals with schizophrenia have consistently lower Apo A1 levels regardless of obesity, suggesting the need to explore Apo A1 not only as a potential biomarker but also as a potential therapeutic target to improve their cardiovascular health and overall well-being.
KEYWORDS: Obesity, Schizophrenia, Apolipoprotein A1, Biomarkers


